Selected Financial Data
since 2018
Income Statement
Moderna Inc., selected items from income statement, long-term trends
US$ in millions
| 12 months ended: | Product sales | Income (loss) from operations | Net income (loss) |
|---|---|---|---|
| Dec 31, 2023 | 6,671) | (4,239) | (4,714) |
| Dec 31, 2022 | 18,435) | 9,420) | 8,362) |
| Dec 31, 2021 | 17,675) | 13,296) | 12,202) |
| Dec 31, 2020 | 200) | (763) | (747) |
| Dec 31, 2019 | —) | (546) | (514) |
| Dec 31, 2018 | —) | (413) | (385) |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Balance Sheet: Assets
Moderna Inc., selected items from assets, long-term trends
US$ in millions
| Current assets | Total assets | |
|---|---|---|
| Dec 31, 2023 | 10,325) | 18,426) |
| Dec 31, 2022 | 13,431) | 25,858) |
| Dec 31, 2021 | 16,071) | 24,669) |
| Dec 31, 2020 | 6,298) | 7,337) |
| Dec 31, 2019 | 1,129) | 1,589) |
| Dec 31, 2018 | 1,563) | 1,962) |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Balance Sheet: Liabilities and Stockholders’ Equity
Moderna Inc., selected items from liabilities and stockholders’ equity, long-term trends
US$ in millions
| Current liabilities | Total liabilities | Financing lease liabilities | Stockholders’ equity | |
|---|---|---|---|---|
| Dec 31, 2023 | 3,015) | 4,572) | 575) | 13,854) |
| Dec 31, 2022 | 4,923) | 6,735) | 1,073) | 19,123) |
| Dec 31, 2021 | 9,128) | 10,524) | 764) | 14,145) |
| Dec 31, 2020 | 4,389) | 4,775) | 134) | 2,561) |
| Dec 31, 2019 | 143) | 415) | 39) | 1,175) |
| Dec 31, 2018 | 223) | 432) | 43) | 1,530) |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Cash Flow Statement
Moderna Inc., selected items from cash flow statement, long-term trends
US$ in millions
| 12 months ended: | Net cash provided by (used in) operating activities | Net cash (used in) provided by investing activities | Net cash provided by (used in) financing activities |
|---|---|---|---|
| Dec 31, 2023 | (3,118) | 4,206) | (1,377) |
| Dec 31, 2022 | 4,981) | (5,176) | (3,448) |
| Dec 31, 2021 | 13,620) | (8,523) | (873) |
| Dec 31, 2020 | 2,027) | (1,672) | 2,033) |
| Dec 31, 2019 | (459) | (15) | 51) |
| Dec 31, 2018 | (331) | (372) | 1,227) |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Per Share Data
Moderna Inc., selected data per share, long-term trends
US$
| 12 months ended: | Basic earnings per share 1 | Diluted earnings per share 2 | Dividend per share 3 |
|---|---|---|---|
| Dec 31, 2023 | -12.33 | -12.33 | 0.00 |
| Dec 31, 2022 | 21.26 | 20.12 | 0.00 |
| Dec 31, 2021 | 30.31 | 28.29 | 0.00 |
| Dec 31, 2020 | -1.96 | -1.96 | 0.00 |
| Dec 31, 2019 | -1.55 | -1.55 | 0.00 |
| Dec 31, 2018 | -4.95 | -4.95 | 0.00 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1, 2, 3 Data adjusted for splits and stock dividends.